Acorda Therapeutics Inc

NASDAQ:ACOR  
0.52
-0.04 (-7.14%)
Earnings Announcements

Acorda Therapeutics Reports First Quarter 2022 Financial Results

Published: 05/11/2022 20:41 GMT
Acorda Therapeutics Inc (ACOR) - Acorda Therapeutics Reports First Quarter 2022 Financial Results.
Acorda Therapeutics Inc - GAAP Net Loss of $25.6 Million for Quarter Ended March 31, 2022, Or $1.93 per Diluted Share.
Acorda Therapeutics Inc - Non-GAAP Net Loss for Quarter Ended March 31, 2022 Was $22.0 Million, Or $1.66 per Diluted Share.
Acorda Therapeutics Inc - at March 31, 2022, Company Had Cash, Cash Equivalents, and Restricted Cash of $51.5 Million.
Acorda Therapeutics Inc - for Full Year 2022, Acorda Continues to Expect Ampyra Net Revenue to Be $68 - $78 Million.
Revenue is expected to be $30.57 Million
Adjusted EPS is expected to be -$1.56

Next Quarter Revenue Guidance is expected to be $31.01 Million
Next Quarter EPS Guidance is expected to be -$1.11

More details on our Analysts Page.